Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Histological diagnosis of thoracic Esophageal squamous cell carcinoma

• ECOG performance status 0-1

• Age 18-75 years

• Resectable disease, cT2-4aNanyM0 or cT1-3N+M0

• Life expectancy more than 6 months

• Use of an effective contraceptive for adults to prevent pregnancy

Exclusion Criteria:

• Not suitable for surgery

• Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC

• Prior esophageal, gastric, or gastro-esophageal junction surgery

• Esophageal ulcer, esophageal perforation，chest pain（≥middle level）

• Pregnant or lactating women